特瑞普利单抗治疗化疗难治性胃癌的安全性、疗效及TMB对总生存获益的预测价值
该Ib/II期试验纳入化疗难治性晚期胃癌患者58例接受特瑞普利单抗单药治疗,另18例初治患者接受特瑞普利单抗联合XELOX一线治疗。单药组客观缓解率12.1%,高TMB组总生存显著优于低TMB组(14.6 vs 4.0个月,HR=0.48,P=0.038),PD-L1过表达与生存获益无显著相关。联合组客观缓解率66.7%,安全性总体可控。
要点
- 化疗难治性胃癌单药特瑞普利单抗客观缓解率12.1%,疾病控制率39.7%。
- 高TMB患者总生存显著优于低TMB患者(14.6 vs 4.0个月,HR=0.48,P=0.038)。
- 特瑞普利单抗联合XELOX一线治疗客观缓解率达66.7%,安全性可控。
核心结论
- 特瑞普利单抗在晚期胃癌中安全性可控并显示抗肿瘤活性,联合XELOX尤为突出。
- 高TMB可能是特瑞普利单抗单药治疗晚期胃癌总生存的预测标志物。
研究设计与样本
- Ib/II期临床试验NCT02915432的晚期胃癌队列。
- 队列1纳入58例化疗难治性患者接受特瑞普利单抗3 mg/kg d1 Q2W单药治疗。
- 队列2纳入18例初治患者接受特瑞普利单抗360 mg d1 Q3W联合奥沙利铂130 mg/m2 d1及卡培他滨1000 mg/m2 bid d1-d14 Q3W一线治疗。
- 主要终点为客观缓解率,评估PD-L1和TMB与临床疗效的相关性。
主要发现
- 队列1客观缓解率12.1%,疾病控制率39.7%,中位无进展生存1.9个月,中位总生存4.8个月。
- 队列1高TMB组总生存显著优于低TMB组(14.6 vs 4.0个月,HR=0.48,96%CI 0.24-0.96,P=0.038)。
- 队列1中PD-L1过表达与显著生存获益无关。
- 队列1有77.6%患者发生至少1项治疗相关不良事件,22.4%发生≥3级治疗相关不良事件。
- 队列2客观缓解率66.7%,疾病控制率88.9%,94.4%患者发生至少1项治疗相关不良事件,38.9%发生≥3级治疗相关不良事件。
关键数值与推荐
- 队列1:客观缓解率12.1%,疾病控制率39.7%,中位无进展生存1.9个月,中位总生存4.8个月。
- 队列1高TMB vs 低TMB总生存:14.6 vs 4.0个月,HR=0.48(96%CI 0.24-0.96),P=0.038。
- 队列2:客观缓解率66.7%,疾病控制率88.9%。
临床怎么用
- 特瑞普利单抗单药可用于化疗难治性晚期胃癌,安全性可控。
- 高TMB或可辅助筛选从特瑞普利单抗单药治疗中总生存获益的晚期胃癌患者。
- 特瑞普利单抗联合XELOX一线治疗晚期胃癌显示较高缓解率,需关注≥3级治疗相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety and efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of TMB and PD-L1. PATIENTS AND METHODS: We reported on the AGC cohort of phase Ib/II trial evaluating the safety and activity of toripalimab in patients with AGC, oesophageal squamous cell carcinoma, nasopharyngeal carcinoma and head and neck squamous cell carcinoma. In cohort 1, 58 chemo-refractory AGC patients received toripalimab (3 mg/kg d1, Q2W) as a monotherapy. In cohort 2, 18 chemotherapy-naive AGC patients received toripalimab (360 mg d1, Q3W) with oxaliplatin 130 mg/m2 qd, d1, capecitabine 1000 mg/m2 b.i.d., d1-d14, Q3W as first-line treatment. Primary end point was ORR. Biomarkers such as PD-L1 and TMB were evaluated for correlation with clinical efficacy. RESULTS: In cohort 1, the ORR was 12.1% and the disease control rate (DCR) was 39.7%. Median PFS was 1.9 months and median OS was 4.8 months. The TMB-H group showed significant superior OS than the TMB-L group [14.6 versus 4.0 months, HR = 0.48 (96% CI 0.24-0.96), P = 0.038], while PD-L1 overexpression did not correlate with significant survival benefit. A 77.6% of patients experienced at least one treatment-related adverse event (TRAE), and 22.4% of patients experienced a grade 3 or higher TRAE. In cohort 2, the ORR was 66.7% and the DCR was 88.9%. A 94.4% of patients experienced at least one TRAE and 38.9% of patients experienced grade 3 or higher TRAEs. CONCLUSIONS: Toripalimab has demonstrated a manageable safety profile and promising antitumor activity in AGC patients, especially in combination with XELOX. High TMB may be a predictive marker for OS of AGC patients receiving toripalimab as a single agent. TRIAL REGISTRATION: ClinicalTrials.gov NCT02915432.
引用
- Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019. PMID: 31236579. doi:10.1093/annonc/mdz197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。